Global Antibody Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Antibody Market was valued at $282 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 11.5% CAGR, to an estimated market size of $487 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global antibody market encompasses the development, production, and commercialization of therapeutic monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies used in human medicine. The scope primarily includes treatments for oncology, autoimmune diseases, and infectious diseases, while excluding diagnostic kits, research-only reagents, and veterinary applications.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Antibody Market in the period 2025-30:
- The rapid adoption of Antibody-Drug Conjugates (ADCs) is transforming oncology by providing highly targeted delivery of cytotoxic agents to cancer cells.
- Integration of Artificial Intelligence (AI) and machine learning is significantly accelerating antibody discovery, sequence optimization, and manufacturing efficiency.
- The market is experiencing a surge in Biosimilar competition as patent expirations for blockbuster biologics drive demand for more cost-effective treatment options.
- A shift toward Precision Medicine is increasing the utilization of antibodies as targeted therapies that offer higher efficacy and fewer side effects than traditional chemotherapy.
- Strategic Regulatory Support from the FDA and EMA, including expedited approval pathways, is shortening the time-to-market for innovative antibody therapies.
- Rising prevalence of Chronic Diseases, particularly autoimmune disorders and solid tumors, remains the primary driver for long-term market volume growth.
- Increased investment in Next-Generation Sequencing (NGS) and genomics is enabling the development of highly specific antibodies for rare disease indications.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Segments
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Bispecifics & Other Modalities